The microRNA signature of patients with sunitinib failure: regulation of  UHRF1  pathways by  microRNA-101  in renal cell carcinoma

Yusuke Goto; Akira Kurozumi; Nijiro Nohata; Satoko Kojima; Ryosuke Matsushita; Hirofumi Yoshino; Kazuto Yamazaki; Yasuo Ishida; Tomohiko Ichikawa; Yukio Naya; Naohiko Seki

doi:10.18632/oncotarget.10887

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

The microRNA signature of patients with sunitinib failure: regulation of UHRF1 pathways by microRNA-101 in renal cell carcinoma

Yusuke Goto, Akira Kurozumi, Nijiro Nohata, Satoko Kojima, Ryosuke Matsushita, Hirofumi Yoshino, Kazuto Yamazaki, Yasuo Ishida, Tomohiko Ichikawa, Yukio Naya and Naohiko Seki _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:59070-59086. https://doi.org/10.18632/oncotarget.10887

Metrics: PDF 2076 views | HTML 3612 views | ?

Abstract

Yusuke Goto1,2, Akira Kurozumi1,2, Nijiro Nohata3, Satoko Kojima4, Ryosuke Matsushita5, Hirofumi Yoshino5, Kazuto Yamazaki6, Yasuo Ishida6, Tomohiko Ichikawa2, Yukio Naya4, Naohiko Seki1

1Department of Functional Genomics, Chiba University Graduate School of Medicine, Chiba, Japan

2Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan

3Moores Cancer Center, University of California, San Diego, La Jolla, CA, United States of America

4Department of Urology, Teikyo University Chiba Medical Center, Chiba, Japan

5Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan

6Department of Pathology, Teikyo University Chiba Medical Center, Chiba, Japan

Correspondence to:

Naohiko Seki, email: [email protected]

Keywords: microRNA, renal cell carcinoma, sunitinib, miR-101, UHRF1

Received: June 20, 2016 Accepted: July 19, 2016 Published: July 28, 2016

ABSTRACT

Molecular targeted therapy is a standard treatment for patients with advanced renal cell carcinoma (RCC). Sunitinib is one of the most common molecular-targeted drugs for metastatic RCC. Molecular mechanisms of sunitinib resistance in RCC cells is still ambiguous. The microRNA (miRNA) expression signature of patients with sunitinib failure in RCC was constructed using a polymerase chain reaction (PCR)-based array. Several miRNAs that were aberrantly expressed in RCC tissues from patients treated with sunitinib were identified in this analysis. MicroRNA-101 (miR- 101) was markedly suppressed in sunitinib treated RCC tissues. Restoration of miR-101 significantly inhibited cell migration and invasion in Caki-1 and 786-O cells. Ubiquitin-like with PHD and ring finger domains 1 (UHRF1) was directly suppressed by miR-101 in RCC cells, and overexpression of UHRF1 was confirmed in sunitinib-treated RCC tissues. The pathways of nucleotide excision repair and mismatch repair were significantly suppressed by knockdown of UHRF1. Our findings showed that antitumor miR-101- mediated UHRF1 pathways may be suppressed by sunitinib treatment.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10887

Publication Alerts

Research Papers:

The microRNA signature of patients with sunitinib failure: regulation of UHRF1 pathways by microRNA-101 in renal cell carcinoma

Abstract